公开(公告)号：US20240002814A1

公开(公告)日：2024-01-04

申请号：US18035149

申请日：2021-11-03

Applicant: Protalix Ltd.

Inventor： Ilya RUDERFER ,  Yakir NATAF ,  Gil ARVATZ ,  Uri HANANIA ,  Tamar ARIEL ,  Shelly ROZEN ,  Yael HAYON

IPC: C12N9/06 ,  A61K38/44

CPC classification number: C12N9/0048 ,  A61K38/44 ,  C12Y107/03003

Abstract: A modified uricase is described herein, as well as a method of reducing a level of uric acid by contacting a medium with the modified uricase. The modified uricase comprises a uricase polypeptide crosslinked by at least one bifunctional linking moiety that comprises a poly(alkylene glycol) moiety. A molecular weight of the bifunctional linking moiety is from about 1.5 kDa to about 4 kDa, and/or the modified uricase comprises a plurality of polypeptides having the amino acid sequence SEQ ID NO: 2. Further described is a polypeptide having the amino acid sequence SEQ ID NO: 2. A process of preparing the modified uricase is also described, comprising contacting the polypeptide with a crosslinking agent that comprises a poly(alkylene glycol) moiety and at least two aldehyde groups, to obtain a conjugate; and contacting the conjugate with a reducing agent.

公开(公告)号：US20240263150A1

公开(公告)日：2024-08-08

申请号：US18429649

申请日：2024-02-01

Applicant: Protalix Ltd.

Inventor： Ilya RUDERFER ,  Yakir NATAF ,  Gil ARVATZ ,  Uri HANANIA ,  Tamar ARIEL ,  Shelly ROZEN ,  Yael HAYON ,  Zohar KEREN ,  Orit COHEN-BARAK

IPC: C12N9/06 ,  A61K9/00 ,  A61K31/519

CPC classification number: C12N9/0048 ,  A61K9/0019 ,  A61K31/519

Abstract: A method of treating a disease or disorder associated with excessive uric acid levels is disclosed herein. The method comprises administering to the subject by i.v. infusion an amount of a recombinant homotetrameric uricase enzyme comprising four uricase polypeptides having the amino acid sequence as set forth in SEQ ID NO: 2, wherein the polypeptides are crosslinked by polyethylene glycol (PEG) bis-aldehyde having a molecular weight of 2-3.5 kDa.

公开(公告)号：US20180148703A1

公开(公告)日：2018-05-31

申请号：US15636753

申请日：2017-06-29

Applicant: Protalix Ltd.

Inventor： Avidor SHULMAN ,  Ilya RUDERFER ,  Tehila BEN-MOSHE ,  Talia SHEKHTER ,  Yaniv AZULAY ,  Tali KIZHNER ,  Yoseph SHAALTIEL

IPC: C12N9/40 ,  A61K38/00

CPC classification number: C12N9/2465 ,  A61K38/00 ,  C12Y302/01022

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

公开(公告)号：US20230416707A1

公开(公告)日：2023-12-28

申请号：US18030291

申请日：2021-10-07

Applicant: Protalix Ltd.

Inventor： Ilya RUDERFER ,  Liat FUX ,  Yael HAYON

IPC: C12N9/22 ,  A61K47/60 ,  A61P1/00 ,  A61P7/00 ,  A61P31/04 ,  A61P9/10 ,  A61P31/12

CPC classification number: C12N9/22 ,  A61K47/60 ,  A61P1/00 ,  A61P7/00 ,  A61P31/04 ,  A61P9/10 ,  A61P31/12 ,  C12Y301/21001

Abstract: A modified DNase protein is described herein as well as pharmaceutical compositions comprising same, the modified DNase protein comprising a DNase polypeptide attached to at least two poly(alkylene glycol) moieties. Further described herein is a process of preparing a modified DNase protein, the process comprising: contacting the polypeptide with an agent that comprises a poly(alkylene glycol) attached to an aldehyde group, to obtain a conjugate of the polypeptide and the agent; and contacting the conjugate with a reducing agent.

公开(公告)号：US20220106578A1

公开(公告)日：2022-04-07

申请号：US17555557

申请日：2021-12-20

Applicant: Protalix Ltd.

Inventor： Lilach CHEN ZELTSBURG ,  Ilya RUDERFER ,  Avidor SHULMAN ,  Liat FUX ,  Yulia UGORTSEV ,  Hagit NETA ,  Sivan GELLEY ,  Elad LAVEE LAVIAD ,  Yoseph SHAALTIEL

IPC: C12N9/22 ,  C12N9/16 ,  A61K38/46 ,  A61P43/00 ,  A61P11/00

Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.

公开(公告)号：US20180112201A1

公开(公告)日：2018-04-26

申请号：US15540264

申请日：2016-01-04

Applicant: Protalix Ltd.

Inventor： Lilach CHEN ZELTSBURG ,  Ilya RUDERFER ,  Avidor SHULMAN ,  Liat FUX ,  Yulia UGORTSEV ,  Hagit NETA ,  Sivan GELLEY ,  Elad LAVEE LAVIAD ,  Yoseph SHAALTIEL

IPC: C12N9/22 ,  A61P11/00 ,  A61P43/00

CPC classification number: C12N9/22 ,  A61K38/00 ,  A61P11/00 ,  A61P43/00 ,  C12N9/16

Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.

公开(公告)号：US20160053247A1

公开(公告)日：2016-02-25

申请号：US14936720

申请日：2015-11-10

Applicant: Protalix Ltd.

Inventor： Avidor SHULMAN ,  Ilya RUDERFER ,  Tehila BEN-MOSHE ,  Talia SHEKHTER ,  Yaniv AZULAY ,  Yoseph SHAALTIEL ,  Tali KIZHNER

IPC: C12N9/40

CPC classification number: C12N9/2465 ,  A61K38/00 ,  C12Y302/01022

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract translation: 本文公开了包含通过连接部分彼此共价连接的至少两个α-半乳糖苷酶单体的多聚体蛋白质结构，以及其制备方法，以及通过施用多聚体蛋白质结构治疗法布里病的方法。 根据在溶酶体条件和血清环境中增强的活性和/或更持久的活性方面，所公开的多聚体蛋白质结构表现出改进的性能。